Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for opht
-0.13 (-4.55%)
Real-time:   2:49PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.71 - 2.84
52 week 2.24 - 4.66
Open 2.83
Vol / Avg. 167,040.00/391,921.00
Mkt cap 98.39M
P/E 1.74
Div/yield     -
EPS 1.56
Shares 36.04M
Beta 1.43
Inst. own 66%
Mar 13, 2018
Ophthotech Corp at Cowen Health care Conference - 9:20AM EDT - Add to calendar
Jan 11, 2018
Ophthotech Corp at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 91.49% -379.93%
Operating margin 91.40% -384.14%
EBITD margin - -382.66%
Return on average assets 394.19% -53.10%
Return on average equity - -
Employees 156 -
CDP Score - -


1 Penn Plz Fl 35
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. Its product candidates include Fovista and Zimura. Fovista is designed to target platelet derived growth factor (PDGF) in combination with anti-vascular endothelial growth factor (VEGF) drugs to disrupt the formation of abnormal new blood vessels in wet AMD. Zimura targets complement factor C5, a central component of the complement cascade. The Company has initiated a Phase II/III clinical trial investigating Zimura for treatment of geographic atrophy.

Officers and directors

David R. Guyer M.D. Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Glenn P. Sblendorio President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
David Francis Carroll Chief Financial Officer, Senior Vice President, Treasurer
Age: 51
Bio & Compensation  - Reuters
Keith Westby Chief Operating Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Barbara A. Wood Esq. Senior Vice President, General Counsel, Secretary
Age: 54
Bio & Compensation  - Reuters
David E. Redlick Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Jane Pritchett Henderson Director
Age: 51
Bio & Compensation  - Reuters
Axel Bolte Independent Director
Age: 45
Bio & Compensation  - Reuters
Thomas Dyrberg M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Michael Jay Ross Ph. D. Independent Director
Age: 67
Bio & Compensation  - Reuters